08/05/2026 | Press release | Distributed by Public on 08/05/2026 14:26
|
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
|
||
|
EXELIXIS, INC.
(Exact name of registrant as specified in its charter)
|
||
| Delaware | 04-3257395 | ||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) | ||||
|
AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN
(Full Title of the Plan)
|
||
|
Copies to:
|
|||||
| Brenda J. Hefti | Raquel Fox | ||||
| Senior Vice President and General Counsel | Skadden, Arps, Slate, Meagher & Flom LLP | ||||
| Exelixis, Inc. | 1440 New York Ave NW | ||||
|
1851 Harbor Bay Parkway
|
Washington, DC 20005 | ||||
|
Alameda, CA 94502
|
|||||
| Large accelerated filer | ý | Accelerated filer |
¨
|
|||||||||||
| Non-accelerated filer |
¨
|
Smaller reporting company |
¨
|
|||||||||||
| Emerging growth company |
¨
|
|||||||||||||
|
Exhibit
Number
|
Exhibit Description
|
Incorporation by Reference
|
Filed
Herewith
|
|||||||||||||||||||||||||||||||||||
|
Form
|
File Number
|
Exhibit/
Appendix
Reference
|
Filing Date
|
|||||||||||||||||||||||||||||||||||
| 4.1 | 10-Q | 000-30235 | 3.1 | 8/5/2021 | ||||||||||||||||||||||||||||||||||
| 4.2 | 10-Q | 000-30235 | 3.2 | 4/30/2024 | ||||||||||||||||||||||||||||||||||
| 4.3 | 8-K | 000-30235 | 3.1 | 12/20/2023 | ||||||||||||||||||||||||||||||||||
| 5.1 |
Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
|
X | ||||||||||||||||||||||||||||||||||||
| 23.1 |
Consent of independent registered public accounting firm
|
X | ||||||||||||||||||||||||||||||||||||
| 23.2 |
Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1)
|
X | ||||||||||||||||||||||||||||||||||||
| 24.1 |
Power of Attorney (contained on signature page hereto)
|
X | ||||||||||||||||||||||||||||||||||||
| 99.1 | 8-K | 000-30235 | 10.1 | 5/29/2026 | ||||||||||||||||||||||||||||||||||
| 107 |
Filing Fee Table
|
X | ||||||||||||||||||||||||||||||||||||
| EXELIXIS, INC. | |||||
| By: |
/s/ Michael M. Morrissey
|
||||
| Michael M. Morrissey, Ph. D. | |||||
| President and Chief Executive Officer | |||||
| Signature | Title | Date | ||||||||||||
|
/s/ MICHAEL M. MORRISSEY
|
Director, President and | August 5, 2026 | ||||||||||||
| Michael M. Morrissey, Ph.D. | Chief Executive Officer (Principal Executive Officer) | |||||||||||||
|
/s/ CHRISTOPHER J. SENNER
|
Executive Vice President and | August 5, 2026 | ||||||||||||
| Christopher J. Senner |
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|||||||||||||
|
/s/ STELIOS PAPADOPOULOS
|
Chairman of the Board | August 5, 2026 | ||||||||||||
| Stelios Papadopoulos, Ph.D. | ||||||||||||||
|
/s/ MARY C. BECKERLE
|
Director | August 5, 2026 | ||||||||||||
| Mary C. Beckerle, Ph.D. | ||||||||||||||
|
/s/ S. GAIL ECKHARDT
|
Director | August 5, 2026 | ||||||||||||
| S. Gail Eckhardt, M.D. | ||||||||||||||
|
/s/ MARIA C. FREIRE
|
Director | August 5, 2026 | ||||||||||||
| Maria C. Freire, Ph.D. | ||||||||||||||
| Signature | Title | Date | ||||||||||||
|
/s/ TOMAS J. HEYMAN
|
Director | August 5, 2026 | ||||||||||||
| Tomas J. Heyman | ||||||||||||||
|
/s/ DAVID E. JOHNSON
|
Director | August 5, 2026 | ||||||||||||
| David E. Johnson | ||||||||||||||
|
/s/ ROBERT L. OLIVER
|
Director | August 5, 2026 | ||||||||||||
| Robert L. Oliver, Jr. | ||||||||||||||
|
/s/ GEORGE POSTE
|
Director | August 5, 2026 | ||||||||||||
| George Poste, DVM, Ph.D., FRS | ||||||||||||||
|
/s/ JULIE A. SMITH
|
Director | August 5, 2026 | ||||||||||||
| Julie A. Smith | ||||||||||||||
|
/s/ JACK L. WYSZOMIERSKI
|
Director | August 5, 2026 | ||||||||||||
| Jack L. Wyszomierski | ||||||||||||||